Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | AGXT | P21549 | 2/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29430341 | 1.00 | DPP4 (0.46) | DPP4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL11029838 | 0.98 | DPP4 (0.44) | DPP4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5038406 | 0.98 | DPP4 (0.44) | DPP4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3307736 | 0.82 | IDO1 (0.40) | DPP4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL30149750 | 0.82 | IDO1 (0.40) | DPP4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL27830893 | 0.81 | DPP4 (0.43) | DPP4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL29453657 | 0.80 | IDO1 (0.54) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL120150 | 0.80 | IDO1 (0.54) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL5252643 | 0.79 | MPO (0.49) | DPP4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7700255 | 0.79 | CA3 (0.46) | DPP4PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 831 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116640106-B | Phenylpiperazine compound and preparation method and application thereof | 郑州大学 | 2024-03-08 | — | — | CN | claimed |
| CN-117586257-A | Compound containing 2, 8-diazaspiro [4.5] decan-1-one skeleton and application thereof | 中国药科大学 | 2024-02-23 | — | — | CN | claimed |
| CN-116640106-A | Phenylpiperazine compound and preparation method and application thereof | 郑州大学 | 2023-08-25 | — | — | CN | claimed |
| US-20080177077-A1 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | PFIZER, INC. | 2008-07-24 | — | — | US | claimed |
| US-12617880-B2 | Compounds for use in catalyst compositions for the production of polyolefins | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2026-05-05 | — | — | US | disclosed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| EP-4605394-A1 | PYRIMIDINE SGC STIMULATORS | Tisento Therapeutics Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250243205-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2025-07-31 | — | — | US | disclosed |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250122171-A1 | Substituted Amine Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-5352678-A | Dopaminergic agents | BRISTOL-MYERS SQUIBB CO. (US) | 1994-10-04 | — | — | US | disclosed |
| EP-0594573-A1 | PREPARATION OF PROPENOIC ACID DERIVATIVES | AgrEvo UK Limited (GB) | 1994-05-04 | — | — | EP | disclosed |
| US-5264609-A | Etherification and hydrolysis | SCHERING AGROCHEMICALS LIMITED (GB) | 1993-11-23 | — | — | US | disclosed |
| EP-0546583-A1 | Piperazinyl-and piperidinyl-cyclohexanols | Bristol-Myers Squibb Company (US) | 1993-06-16 | — | — | EP | disclosed |
| WO-1991007385-A1 | PREPARATION OF PROPENOIC ACID DERIVATIVES | SCHERING AGROCHEMICALS LIMITED (GB) | 1991-05-30 | — | — | WO | disclosed |
| US-4695579-A | Antifungal 2-azolylmethyl-3-difluorobenzyloxy-2,3-dihydrofluoro-benzo(B) thiophens | SCHERING CORPORATION (US) | 1987-09-22 | — | — | US | disclosed |
| EP-0185381-A2 | 2-Azolylmethyl-3-difluorobenzyloxy-2,3-dihydrofluorobenzo(b)thiophenes, process for their preparation and compositions containing them | SCHERING CORPORATION (US) | 1986-06-25 | — | — | EP | disclosed |
| EP-0157637-A2 | Heterocyclic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1985-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | DPP4 109/4885PSEN1 4382/4885PSEN2 4657/4885 |
| US-12617880-B2 | Compounds for use in catalyst compositions for the production of polyolefins | PRMT5, CBR3, MET | DPP4 4636/4885PSEN1 4753/4885PSEN2 4736/4885 |
| US-20250122171-A1 | Substituted Amine Compounds, Compositions and Methods of Use | MRGPRX2, MRGPRX1, MRGPRX4 | DPP4 2501/4885PSEN1 2497/4885PSEN2 1073/4885 |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | DPP4 3964/4885PSEN1 263/4885PSEN2 1218/4885 |
| US-20250243205-A1 | sGC STIMULATORS | GMPS, GUCY1A2, PDE2A | DPP4 2780/4885PSEN1 3549/4885PSEN2 3765/4885 |
| US-20080177077-A1 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | CYP4X1, CYP4B1, KDM4B | DPP4 871/4885PSEN1 3711/4885PSEN2 2463/4885 |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | DPP4 2451/4885PSEN1 3200/4885PSEN2 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.